Skip to main content
. 2021 Jun 21;5(12):2624–2643. doi: 10.1182/bloodadvances.2021004629

Table 4.

Pooled estimates of SC to 1 or 2 doses of the pandemic influenza vaccine in patients treated with anti-CD20 therapy

Pooled estimate of SC, % (95% CI, I2 %)
Duration of time since last anti-CD20 treatment, mo No. of studies Total no. of patients  For 1 vaccine dose  For 2 vaccine doses
Active, <3 6 75 3 (0-9, 0) 12 (2-27, 37)
3-6 2 21 21 (0-65, 71) 4 (0-32, 0)
6-12 1 12 50 (4-96, N/A) 50 (4-96, N/A)
>12 2 26 41 (19-65, 0) 75 (39-100, 41)

N/A, not applicable.